Personalized pacing for HFpEF patients with pacemakers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center mechanistic study at Tufts Medical Center evaluating individualized myPACE pacemaker programming in HFpEF patients with an existing pacemaker. Participants will cycle through periods of standard pacing and personalized pacing with serial physiologic assessments. Outcomes include exercise capacity, cardiac function, biomarkers, quality of life, and clinical events. The trial focuses on determining if tailored pacing can optimize hemodynamics and patient experience in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Diagnosis of heart failure with preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction (LVEF) ≥50% with symptoms and signs consistent with heart failure as determined by the treating investigator.
* New York Heart Association (NYHA) Class II or III symptoms despite stable, maximally tolerated guideline-directed medical therapy.
* Pre-existing FDA-approved cardiac physiologic pacemaker (e.g., conduction system pacing or cardiac resynchronization therapy) implanted for a standard clinical indication and capable of individualized lower-rate programming.
* Expected to require ongoing pacemaker therapy throughout the study period.
* Clinically stable at enrollment, without recent major changes in heart failure status that, in the opinion of the investigator, would interfere with interpretation of study outcomes.
* Able and willing to provide written informed consent.
* Able and willing to comply with all study procedures, including pacemaker programming, cardiopulmonary exercise testing (CPET), echocardiography, blood pressure measurements, autonomic testing, blood collection, and follow-up visits.

Exclusion Criteria:

* Age \<18 years.
* Left ventricular ejection fraction \<50%.
* Pregnancy, breastfeeding, or women of childbearing potential unwilling to use an acceptable method of contraception during study participation.
* Inability or unwillingness to provide informed consent.
* Inability to safely perform study procedures, including CPET or autonomic testing, in the opinion of the investigator.
* Any medical condition or life expectancy that, in the opinion of the investigator, would make participation unsafe or would substantially interfere with completion of the study or interpretation of study results.
* Enrollment in another interventional clinical trial that, in the opinion of the investigators, could interfere with this study or confound interpretation of the results.
* Prisoners, wards of the state, or other individuals for whom participation would not be permissible under applicable regulations or institutional policy.

Where it's running

• Tufts Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Margaret Infeld, MD, MS — Tufts Medical Center
• Study coordinator: Courtney Uek
• Email: courtney.uek@tuftsmedicine.org
• Phone: 617-636-4354

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Selenium supplementation for people with heart failure

  This trial will test whether taking a daily selenium supplement helps people with heart failure avoid hospitalization and reduce the risk of death.

  Recruiting at 11 sites Phase 3 Skane University Hospital · Oslo and 10 other locations · NCT07543562

• Preventing obesity-related HFpEF

  We will follow about 250 adults with obesity who are having metabolic bariatric surgery to see if weight loss prevents or reverses early HFpEF.

  Recruiting Zuyderland Medisch Centrum · Heerlen, Limburg · NCT07539766

• Sacituzumab tirumotecan with or without pembrolizumab in ovarian clear cell cancer that has come back or spread

  This phase II study tests Sacituzumab tirumotecan alone or with pembrolizumab in adults whose ovarian clear cell cancer has recurred or spread after prior PD-1 therapy.

  Recruiting Phase 2 Tufts Medical Center · Boston, Massachusetts · NCT07718854

• Outcomes of Oncoplastic Breast Surgery and Goldilocks Mastectomy at Tufts Medicine

  This study will look at past and future surgical results and patient satisfaction after oncoplastic breast surgery or Goldilocks mastectomy at Tufts Medicine to see how patients fare over time.

  Recruiting Tufts Medical Center · Boston, Massachusetts and 1 other locations · NCT07597837

• Pulmonary embolism with right-to-left heart or lung shunts

  This project will see if people with an acute pulmonary embolism who also have a right-to-left shunt (like a PFO or ASD) are more likely to have a stroke than PE patients without a shunt.

  Recruiting Tufts Medical Center · Boston, Massachusetts · NCT07519876

• Veverimer to reduce acid load and slow bone loss in adults with osteopenia

  This trial will test whether taking veverimer, compared with placebo, lowers urinary acid levels and reduces bone breakdown in adults aged 50 and older with osteopenia.

  Recruiting Phase 1 Tufts Medical Center · Boston, Massachusetts · NCT07473713

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.